Antoine Papiernik, Managing Partner and Chairman at Sofinnova Partners, gives CNBC his predictions for what’s next in biotech

Antoine Papiernik appeared on CNBC's Worldwide Exchange to explain his thinking around what to expect in the biotech venture capital space.

Biotech is booming, Papiernik said, "because of the small, innovative companies that are bringing drugs to market." He added that 2018 saw record FDA approvals, proving that "this industry is producing results."

Papiernik said oncology would remain a top priority in biotech research, with neurodegenerative diseases like Alzheimer's and Parkinson's garnering a lot of attention as populations age.

Asked what he was looking for in start-ups, Papiernik said it was important to focus on great science, and be prepared to kill projects that don't have a chance to make a big impact on patients' health.

Watch the full interview on the CNBC website.